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Introduction
============

Kidney transplantation is the preferred treatment for end stage kidney disease. Short and medium term outcomes for transplant recipients are excellent,[@ref1] but mortality is significant in the long term, in large part due to malignancy.[@ref2] Transplant recipients need long term immunosuppressive treatment to prevent graft loss, and this has been associated with an increased risk of cancer.[@ref3] [@ref4] Although the greatest relative increase in risk has been seen for non-melanoma skin cancers and cancers associated with viral infection,[@ref3] the risk of more common solid organ cancers, including colorectal cancer, is also significantly increased with a relative risk compared with the general population of between two and three.[@ref3] [@ref4] [@ref5] Transplant recipients who develop colorectal cancer are often younger at diagnosis and have poorer outcomes when compared with the general population.[@ref5] [@ref6] [@ref7] [@ref8] [@ref9]

Colorectal cancer is the third most commonly diagnosed cancer worldwide[@ref10]; major risk factors include age, male sex, and a family history, and survival is strongly linked to the stage of cancer at diagnosis.[@ref11] In the general population, screening with guaiac based faecal occult blood tests followed by colonoscopy in people with a positive test has been shown to reduce the mortality of colorectal cancer.[@ref12] Faecal occult blood screening is recommended in people over the age of 50 with average risk.[@ref13] [@ref14] [@ref15] [@ref16] Immunochemical tests specific for faecal human haemoglobin have largely replaced the guaiac based tests used in early trials, on the basis of improved acceptability and performance.[@ref17] [@ref18] The effectiveness of screening depends on the identification and removal of colorectal adenomatous polyps with features associated with an increased risk of malignant transformation and early stage malignant disease, together termed "advanced colorectal neoplasia."[@ref19] Colonoscopy can also been used to screen patients at average risk,[@ref20] [@ref21] [@ref22] [@ref23] but this is associated with higher costs, less convenience, and the potential for adverse outcomes in a small number of patients.[@ref24] It is, however, accepted as the most appropriate screening test for patients at moderate to high risk of colorectal cancer.[@ref13] [@ref14] [@ref15] [@ref25]

No studies have been published on the benefits or harms of screening kidney transplant recipients for colorectal cancer. Clinical practice guidelines for the care of kidney transplant recipients have suggested screening from the age of 50 years with faecal haemoglobin and that this might be cost effective.[@ref26] [@ref27] [@ref28] However, the prevalence of advanced colorectal neoplasia is unknown, as is the diagnostic accuracy of faecal haemoglobin testing in kidney transplant recipients. Importantly, faecal haemoglobin might be less specific for colorectal neoplasia owing to the incidence of positive tests from colitis due to cytomegalovirus infection or toxicity of immunosuppressive drugs, for example.[@ref26] In addition, no data have been published on the safety of colonoscopy in transplant recipients, which might have increased harms due to the negative influence of immunosuppression.[@ref26]

To fill this gap in available data, we did a cross sectional study of prevalence and diagnostic accuracy in a kidney transplant recipient population, using both faecal haemoglobin testing and colonoscopy to determine the prevalence and characteristics of advanced colorectal neoplasia and to evaluate the diagnostic accuracy of a faecal immunochemical test for human haemoglobin (the index test) compared with colonoscopy (the reference standard) to detect advanced colorectal neoplasia in this population.

Methods
=======

Study design, setting, and participants
---------------------------------------

This was a population based, cross sectional study of prevalent kidney transplant recipients, conducted through outpatient clinics at metropolitan and regional hospitals in the state of South Australia. Three tertiary renal services, which collectively care for all adult transplant recipients in the state, were involved. The study took place between June 2008 and October 2011.

Kidney transplant recipients were eligible if they were aged over 50 years, were at least six months post-transplant, and gave written informed consent. Patients were invited to participate during the course of routine follow-up in the outpatient clinic. Exclusion criteria were previous colorectal cancer or adenoma with high grade dysplasia, colonoscopy within 12 months, symptoms or signs suggestive of colorectal cancer or other significant non-neoplastic colorectal disease, known or suspected familial colorectal cancer syndrome (patients with cancer in one close relative were eligible), chronic inflammatory bowel disease, unstable cardiopulmonary disease, bleeding disorder or unacceptable risk of bleeding, terminal illness or life threatening malignancy, or a failed transplant and subsequent return to dialysis.

Patients with a history of previous rectal bleeding attributed to haemorrhoids or other non-neoplastic disease were eligible provided bleeding was not an active problem. Patients receiving anticoagulant treatment were also eligible provided they could discontinue this treatment at the time of screening colonoscopy, if requested by the endoscopist. Patients who had had a previous faecal haemoglobin test, colonoscopy, or both were eligible provided they did not meet any of the other exclusion criteria.

Study procedures
----------------

Study participants completed a faecal immunochemical test for human haemoglobin by using the Enterix Insure kit (Enterix Australia). This test uses a brush to obtain each faecal sample, which is then applied to a testing card; two samples are taken from consecutive bowel motions. Participants completed a questionnaire concerning timing of the samples, colorectal symptoms, and details of colorectal disease, previous screening, and family history. A history of anticoagulant or antiplatelet drug use and allergies was also sought. We reviewed medical records to provide additional data.

De-identified test cards were forwarded to a central laboratory (Enterix Australia, Sydney) for processing using methods previously described.[@ref18] Study investigators had no involvement in the laboratory analysis of samples.

After faecal testing, and regardless of the result, participants were referred for colonoscopy. To reduce the risk of dropout, participants were informed of faecal haemoglobin results before colonoscopy only on request. Interventional gastroenterologists and colorectal surgeons did colonoscopies; to meet ethical clearance requirements, we could not blind physicians to the faecal haemoglobin result. In the three major participating centres, specific colonoscopy lists were arranged for this study; colonoscopies were also done in regional hospitals and in the private sector.

Participants received bowel preparation according to the endoscopist's preference---usually a polyethylene glycol based preparation alone or in combination with a sodium picosulfate based preparation. Sodium phosphate preparations were not used. At physicians' discretion, participants could be admitted for intravenous hydration before colonoscopy. Participants had a serum creatinine measurement to estimate renal function (glomerular filtration rate) before and after colonoscopy.[@ref29] Any adverse events were noted.

During colonoscopy, the location and size of all polypoid lesions were recorded, and the presence of any other lesions was noted. We defined location within the colon as either proximal (caecum, ascending or transverse colon), distal (descending or sigmoid colon), or in the rectum. Biopsy forceps were used to estimate the size of each polyp. If the examination of the bowel was incomplete because of failure to reach the caecum or poor bowel preparation, the patient was asked to return for a second attempt at the discretion of the endoscopist; we included combined results in the analysis when this occurred within six months of the date of the original colonoscopy. If a participant had surgery as a result of colonoscopy findings, we included results from surgically resected specimens in the analysis.

Classification of index test and reference standard results
-----------------------------------------------------------

We recorded faecal immunochemical test results as either positive or negative for the presence of human haemoglobin, as reported by the laboratory. Retrieved colorectal biopsy samples were sent to local laboratories for histological examination. Pathologists were not aware of the faecal haemoglobin result or that patients were enrolled in this study. The final diagnosis for each participant was determined on the basis of combined results of colonoscopy and histology of retrieved or resected specimens.

To calculate the prevalence of advanced colorectal neoplasia, as well as other pathology, we classified participants on the basis of their most advanced lesion. For example, we classified a participant with an adenoma with high grade dysplastic changes and a tubular adenoma as having an advanced adenoma with high grade dysplasia. We defined advanced colorectal neoplasia, in accordance with previous studies,[@ref20] [@ref21] [@ref22] as the presence of either cancer or an advanced adenoma---a tubular adenoma of at least 10 mm diameter, a villous or tubulovillous adenoma (that is, at least 25% villous), or an adenoma with high grade dysplasia. We diagnosed and staged cancer according to the American Joint Committee on Cancer's classification.[@ref30]

Data analysis
-------------

We used Stata software version 11.2 for all statistical analyses. We express data as raw values and percentages for categorical data and as mean (standard deviation) or median (interquartile range) for continuous data. We used Student's *t* test to compare continuous variables and logistic regression to determine associations between categorical variables. We set statistical significance for hypothesis testing at 0.05 (that is P≤0.05). All statistical tests were two tailed.

To evaluate the diagnostic accuracy of faecal haemoglobin to detect advanced colorectal neoplasia, we compared results with colonoscopy findings by using two by two tables. We calculated sensitivity, specificity, positive and negative predictive values, likelihood ratios, and diagnostic odds ratios. We present estimates with 95% confidence intervals.

Sample size
-----------

We estimated the prevalence of advanced colorectal neoplasia in transplant recipients to be 12%, on the basis of a general population prevalence of approximately 6%[@ref23] and transplant registry data suggesting an increased risk of colorectal cancer in transplant recipients of at least twofold. We estimated that a sample size of 218 participants would allow us to detect a prevalence (proportion) of advanced neoplasia of 12% (0.12), with a resulting binomial exact 95% confidence interval that ranged from 7.9% to 17.0% (that is, less than 5% in either direction). Assuming a completion rate of 60-70%, we sought to target between 310 and 360 patients for recruitment.

Results
=======

Participants
------------

From information available from hospital units' records, we estimated that the population of eligible transplant recipients in South Australia would be approximately 400 patients. Between 1 June 2008 and 30 June 2011, 360 patients were assessed for initial eligibility and invited to participate. The figure[](#fig1){ref-type="fig"} shows the flow of patients through the study, along with the primary outcome of advanced colorectal neoplasia. Patients who were excluded (and reasons for this) or who withdrew from the study are noted. In total, 229 patients completed the study, a completion rate of 64%; table 1[](#tbl1){ref-type="table"} outlines the characteristics of these participants. Twenty-six (10%) patients who completed faecal haemoglobin testing did not have colonoscopy and were excluded from analysis. Table 2[](#tbl2){ref-type="table"} shows details of previous colorectal history and screening. Outcomes for all participants were finalised according to available results as at 31 October 2011.

![**Fig 1** Flow of participants through study](colm004749.f1_default){#fig1}

###### 

 Characteristics of study participants who completed screening. Values are numbers (percentages) unless stated otherwise

  Characteristic                                                     Value (n=229)
  ------------------------------------------------------------------ ---------------
  Mean (SD) age (years):                                             
   At transplant                                                     52.6 (10.3)
   At screening                                                      61.5 (6.9)
  Male sex                                                           151 (66)
  Time since transplant (years):                                     
   \<5                                                               97 (42)
   5-10                                                              57 (25)
   10-15                                                             35 (15)
   15-20                                                             16 (7)
   \>20                                                              24 (10)
   Mean (SD)                                                         9.0 (8.4)
   Median                                                            6.5
  Renal function:                                                    
   Mean (SD) serum creatinine (µmol/L)                               122.2 (47.3)
   Mean (SD) MDRD eGFR (mL/min/1.73 m^2^)                            55.1 (19.3)
  Cause of end stage kidney disease:                                 
   Glomerulonephritis                                                127 (55)
   Polycystic kidney disease                                         32 (14)
   Diabetic nephropathy                                              20 (9)
   Hypertension                                                      8 (3)
   Other                                                             36 (16)
   Unknown                                                           6 (3)
  Deceased donor                                                     189 (83)
  Second or subsequent transplant                                    29 (13)
  Immunosuppressive drugs at time of screening:                      
   Triple---ciclosporin based (+ MMF/azathioprine and steroids)      24 (10)
   Triple---tacrolimus based (+ MMF/azathioprine and steroids)       53 (23)
   Triple---mTOR inhibitor based (+ MMF/azathioprine and steroids)   45 (20)
   Dual---ciclosporin based (+ MMF/azathioprine)                     35 (15)
   Dual---tacrolimus based (+ MMF/azathioprine)                      12 (5)
   Dual---mTOR inhibitor (+ MMF/azathioprine)                        10 (4)
   Dual---MMF/azathioprine + steroids                                25 (11)
   Other (including steroid or MMF alone, experimental agents)       21 (9)
   Not on immunosuppression at time of screening                     1 (\<1)
   Not recorded                                                      1 (\<1)
  Current or former smoker                                           86 (38)
  History of other significant medical conditions:                   
   Cardiovascular disease                                            93 (41)
   Diabetes                                                          81 (35)
   Chronic lung disease                                              23 (10)
  Previous malignancy:                                               
   Non-melanoma skin cancer (SCC or BCC)                             75 (33)
   Other\*                                                           20 (9)
  Antiplatelet or anticoagulant drug use:                            
   Aspirin                                                           69 (30)
   Clopidogrel                                                       8 (3)
   Warfarin                                                          19 (8)

BCC=basal cell carcinoma; MDRD eGFR=glomerular filtration rate estimated using four variable modification of diet in renal disease equation; MMF=mycophenolic acid derivative (mycophenolate mofetil or mycophenolic acid sodium); mTOR inhibitor=mammalian target of rapamycin inhibitor (sirolimus or everolimus); SCC=squamous cell carcinoma.

\*Melanoma (n=4); prostate (n=4); bladder (n=3); cervical (n=2); head and neck (n=2); renal (n=2); endometrium (n=1); breast (n=1); lymphoma (n=1); leukaemia (n=1).

###### 

 Reported colorectal history and previous screening of study participants

  Reported participants' history item                                       No (%) (n=229)
  ------------------------------------------------------------------------- ----------------
  Family history of colorectal cancer in first degree relative\*            24 (10)
  History of non-neoplastic colorectal disease (not polyps):                
   Any non-neoplastic disease                                               14 (6)
   Diverticulosis                                                           11 (5)
   Other                                                                    3 (1)
  History of colonic polyps:                                                
   Any polyps                                                               17 (7)
   Previous low grade tubular adenomas                                      8 (3)
   Polyps---details unknown or unspecified                                  9 (4)
  History of rectal bleeding before study:                                  
   Any rectal bleeding                                                      57 (25)
   Haemorrhoids                                                             35 (15)
   Other non-neoplastic causes (anal fissure, diverticulitis, other)        22 (10)
  Rectal bleeding reported initially at time of faecal sample submission:   
   Within 4 weeks of sampling                                               1 (\<1)
   At time of faecal sampling                                               0
  Previous faecal screening for human haemoglobin/occult blood:             
   Any                                                                      79 (34)
   Known positive result in past                                            9 (4)
  Previous colonoscopy (screening or otherwise) at any time                 78 (34)
  Previous colonoscopy after transplant:                                    
   At any time after transplant                                             38 (17)
   Within 1-5 years of screening study                                      21 (9)
   \>5 years before screening study                                         17 (7)
  Previous colonoscopy before transplant:                                   
   At any time before transplant                                            40 (17)
   Within 1-5 years of screening study                                      19 (8)
   \>5 years before screening study                                         21 (9)

\*More than one affected first degree relative was an exclusion criterion; no participants reported this.

Quality of faecal haemoglobin testing and colonoscopy
-----------------------------------------------------

Faecal testing cards were developed a mean of 9.0 (SD 4.4) days after the first faecal sample was taken and 8.2 (4.1) days after the second sample. The median interval between the faecal haemoglobin result and completion of colonoscopy was 82 (interquartile range 47-135) days.

The caecum was intubated in 219 (96%) of 229 screening colonoscopies. Colonoscopy was incomplete in six cases; screening was supplemented with computed tomographic colonography (n=2), barium enema (n=2), or a repeat colonoscopy 12 months later (n=1). One participant did not attend the appointment for computed tomographic colonography. In four cases, no data on caecal intubation was recorded in the colonoscopy report.

Views of the bowel were considered at least partly reduced because of suboptimal preparation in 36 (16%) participants. Seven (3%) participants returned for a follow-up colonoscopy with improved preparation and had composite results from both procedures included in study outcomes.

Primary outcomes
----------------

Table 3[](#tbl3){ref-type="table"} shows the final diagnoses after colonoscopy, classified according to the most advanced lesion. Overall, 29 (13%, 95% confidence interval 9% to 18%) participants had advanced colorectal neoplasia; 4 (2%) participants had a high grade dysplastic lesion, and 5 (2%) had previously undiagnosed colorectal cancer. The appendix gives further details of the location and staging of the cancer and the surgical procedure performed. In addition to the participants who had surgery for cancer, one participant with a large adenoma had a right hemicolectomy.

###### 

 Final diagnosis in study participants, according to most advanced lesion

  Diagnosis                                             No (%) (n=229)
  ----------------------------------------------------- -------------------------
  Normal or non-neoplastic disease                      157 (69)
  Non-advanced adenoma                                  43 (19)
  Advanced adenoma:                                     24 (10)
   Tubular adenoma ≥10 mm                               11 (5)
   Villous/tubulovillous adenoma (regardless of size)   9 (4)
   High grade dysplasia (regardless of size)            4 (2)
  Colorectal cancer                                     5 (2)
  Prevalence of advanced colorectal neoplasia           29 (13, 95% CI 9 to 18)

Faecal haemoglobin was positive in 28 (12%, 8% to 17%) participants. We found no association between a previous history of visible rectal bleeding or the use of aspirin, warfarin, or clopidogrel and the faecal haemoglobin result (P\>0.05). Tables 4[](#tbl4){ref-type="table"} and 5[](#tbl5){ref-type="table"} show analyses of the diagnostic accuracy of faecal haemoglobin to detect advanced colorectal neoplasia. Among the five participants ultimately diagnosed as having cancer, three had positive faecal haemoglobin (sensitivity of 60%); the tumour's location was not associated with the faecal haemoglobin result (P\>0.05).

###### 

 Two by two table of faecal haemoglobin (index test) results versus colonoscopy (reference standard) for detection of advanced colorectal neoplasia

  Advanced colorectal neoplasia   Faecal haemoglobin result   Total   
  ------------------------------- --------------------------- ------- -----
  Present                         9                           20      29
  Absent                          19                          181     200
  Total                           28                          201     229

###### 

 Diagnostic accuracy estimates of faecal haemoglobin screening for detection of advanced colorectal neoplasia

  Parameter                       Point estimate (95% CI)
  ------------------------------- -------------------------
  Sensitivity (%)                 31.0 (15.3 to 50.8)
  Specificity (%)                 90.5 (85.6 to 94.2)
  Positive predictive value (%)   32.1 (15.9 to 52.4)
  Negative predictive value (%)   90.1 (85.1 to 93.8)
  Positive likelihood ratio       3.27 (1.64 to 6.52)
  Negative likelihood ratio       0.762 (0.595 to 0.977)
  Diagnostic odds ratio           4.29 (1.75 to 10.60)

Of the 72 participants with neoplasia, 18 (8%) had two or more adenomas and seven (3%) had three or more. One participant with colorectal cancer also had a tubulovillous adenoma. In addition to colorectal neoplasia, non-neoplastic disease was frequently detected; the most common diagnoses were diverticular disease (n=76; 33%) and haemorrhoids (n=23; 10%). The appendix gives further details of the location of lesions and of non-neoplastic disease.

Safety of colonoscopy and adverse events
----------------------------------------

No significant adverse events occurred as a result of colonoscopy. Four (2%) patients had minor bleeding in association with polypectomy that was controlled endoscopically. Other minor adverse events are noted in the appendix.

Renal function results were available before and after colonoscopy for 226 participants (three had data missing). Mean estimated glomerular filtration rate did not change (55.1 (SD 19.3) versus 54.5 (19.4) mL/min/1.73 m^2^; P\>0.05, paired *t* test).

Twenty-one (9%) participants were admitted to hospital for intravenous hydration (mean creatinine 171.0 (80.6) μmol/L) before colonoscopy. No adverse outcomes were noted in this group.

Sensitivity and subgroup analyses
---------------------------------

We did a sensitivity analysis to determine if the diagnostic accuracy of faecal haemoglobin testing would be significantly affected by verification bias due to the exclusion of 26 patients who did not have colonoscopy. To estimate the effect of missing reference standard data, we assumed hypothetical best case and worst case scenarios from the perspective of faecal testing and added the results to the observed data: best case---positive = advanced neoplasia present, negative = prevalence of advanced neoplasia same as observed data for negative faecal haemoglobin results (10%); worst case---positive = no advanced neoplasia, negative = double prevalence advanced neoplasia (20%). Under these scenarios, sensitivity reduced slightly (range 26.5-30.3%); specificity was largely unchanged (91.0-91.4%).

To take account of "suboptimal" colonoscopy (that is, caecum not intubated or poor preparation, without a follow-up procedure) or a long interval between faecal sampling and colonoscopy (\>6 months), we estimated diagnostic accuracy separately with these participants excluded. Faecal haemoglobin performed slightly better with optimal colonoscopy (n=188 participants), with an increase in sensitivity (36.0%, 18.0% to 57.5%), specificity (92.0%, 86.7% to 95.7%), and the diagnostic odds ratio (6.49, 2.46 to 17.3). No improvement occurred when we excluded longer time intervals (n=196; diagnostic odds ratio 3.71, 1.5 to 9.24).

Predictors of colorectal neoplasia
----------------------------------

In univariate logistic regression analyses, the only characteristic of participants that was significantly associated with an increased risk of cancer was age (unadjusted odds ratio 1.16 (95% confidence interval 1.01 to 1.33) per year). We found similar results when we analysed age in 5 year bands (odds ratio 2.07 (1.04 to 4.13) for every 5 years above 55). All patients diagnosed as having cancer were male; none had had previous screening colonoscopy or a family history of cancer. No identifiable characteristics of patients were significantly associated with advanced neoplasia.

Previous screening for colorectal cancer
----------------------------------------

Seventy-eight (34%) participants had had one or more colonoscopies before enrolment in this study (table 2[](#tbl2){ref-type="table"}). A family history of colorectal cancer (odds ratio 2.37, 1.10 to 5.10) and a history of rectal bleeding (2.00, 1.09 to 3.68) were both associated with a previous colonoscopy. We did not find any significant differences in the rates of advanced and non-advanced neoplasia between participants who had had previous screening in a post hoc analysis (data not shown).

Discussion
==========

In a population of asymptomatic kidney transplant recipients aged over 50 years at otherwise average risk for colorectal cancer, we found a high prevalence of advanced colorectal neoplasia (13%, 95% confidence interval 9% to 18%). To detect one case of advanced colorectal neoplasia, 8 (6 to 12) participants needed to have colonoscopy. Faecal haemoglobin had poor sensitivity (31.0%, 15.3% to 50.8%) but reasonable specificity (90.5%, 85.6% to 94.2%) for advanced neoplasia. If colonoscopy had been done only after a positive faecal haemoglobin test (as in population screening), three participants would have needed to have colonoscopy for each case identified, but 20 (69%) cases of advanced neoplasia would have gone undetected.

This is the first study to evaluate faecal haemoglobin screening for colorectal neoplasia in kidney transplant recipients, and it is the only study of colonoscopy surveillance among transplant recipients of a similar age and risk profile to the general population included in trials of screening that showed reduced mortality from colorectal cancer. This study presents for the first time prospective data on the safety of routine surveillance colonoscopy in kidney transplant recipients and shows that this can be implemented without adverse effects in a population with a wide range of renal function and comorbidity.

Strengths and limitations of study
----------------------------------

This study has several important strengths. We recruited a high proportion of potentially eligible transplant recipients in South Australia, reaching the target sample size in just over three years. Of 360 patients who were identified, 71% enrolled and submitted a faecal sample, and 64% completed the study---a high rate for a study involving an intervention such as colonoscopy, reducing the potential for selection bias. Quality of performance of colonoscopy was high (96% caecal intubation rate); the diagnostic accuracy of faecal haemoglobin was not significantly affected when suboptimal colonoscopies were excluded. A sensitivity analysis indicated that the 10% of participants excluded because of not having a colonoscopy would not have introduced a significant risk of verification bias.

Because we included a broad range of patients, from both metropolitan and regional settings (not just those cared for at the transplanting centre), who had colonoscopies done in a variety of setting by a variety of operators, these results are more likely to be generalisable to other transplant populations, although the high participation rate achieved could be argued to reflect a cohort of patients that is more compliant and cooperative than might be found in other jurisdictions. However, the demographic and comorbidity profiles of the participants in this study are similar to those of the transplant population aged over 50 years in Australia as a whole and those reported in international comparisons.[@ref1] [@ref2] [@ref31] We chose an age of eligibility of 50 years on the basis that current guidelines recommend starting screening from this age onwards.[@ref13] [@ref14] [@ref16] Although evidence shows that the relative risk of colorectal cancer is highest in younger transplant patients,[@ref5] the absolute risk in those aged under 50 remains low. Sex, family history, and a history of rectal bleeding due to non-neoplastic disease were not discriminating factors, and screening was offered from six months after transplantation, although the median time post-transplant was 6.5 years.

A potential criticism of our study is that we used a cross sectional design without a control (that is, non-transplant recipient) group, which limits our ability to directly compare the findings with the general population. However, this study was designed to fill the gaps in evidence for screening of transplant recipients, rather than as a comparison with the general population. Doing a large scale colonoscopy study in a comparable general population cohort truly at average risk would have been ethically and logistically difficult, given established screening guidelines and that a population screening programme has been implemented in Australia, similar to those in other countries.[@ref14] [@ref32] [@ref33] Such a study of participants at average risk selected from the general population by using electoral (voter) registrations encountered difficulties in recruiting participants to have colonoscopy and produced limited results.[@ref34]

This study has limited statistical power to identify predictors of risk of neoplasia or to compare subgroups owing to the relatively small number of cases of advanced colorectal neoplasia and cancer. Larger studies in multiple jurisdictions would be needed to identify sufficient cases to investigate the relations between factors such as immunosuppressive drugs or other transplant related factors and colorectal neoplasia.

Although laboratory analysis of faecal samples and the interpretation of histology were done in a blinded fashion, we were not able to blind endoscopists to the faecal haemoglobin result. This was because of ethical requirements to ensure that abnormal test results were made available. This may have introduced "expectation" bias through greater effort being made to identify neoplastic disease at colonoscopy after a positive result and might potentially have increased the specificity of faecal haemoglobin. However, in clinical practice this information would always be available to a physician doing colonoscopy.

In our study, we included participants who had had a previous colonoscopy, as long as it was more than a year before enrolment in the study. This creates a potential for "conservative" bias and implies that the prevalence of neoplasia in a population of participants naive to screening might be higher than our findings suggest. However, we judged it inappropriate to exclude such participants on the basis that little has been known about the development or progression of pre-malignant colorectal neoplasia in transplant recipients, whereas the poorer outcomes from cancers in this group have been reported for some time.[@ref6] [@ref7] [@ref9] None of the cancers identified in this study was found in a pre-screened patient, although no differences existed in the rates of advanced and non-advanced adenomas between previously screened and screen naive participants.

Comparisons with other studies
------------------------------

In a meta-analysis of studies of screening with colonoscopy in the general population, with a similar age, sex, and family history profile to this study, the prevalence of colorectal cancer was 0.78% (0.13% to 2.97%) and that of advanced neoplasia was 5.0% (4.0% to 6.0%).[@ref23] The finding of a prevalence estimate of advanced colorectal neoplasia (the precursor to colorectal cancer) in this study of 13% (that is, approximately twice the prevalence in the general population) is consistent with other studies showing a standardised incidence ratio of colorectal cancer of approximately two to three in transplant recipients.[@ref3] [@ref4] [@ref5] The increased risk of many types of cancers in transplant recipients has been associated with immunosuppression[@ref3]; however, we were not able to show an association between the duration or type of immunosuppression and neoplasia, perhaps because of the relatively small number of cases. Other as yet unrecognised factors may also have contributed to the increased risk of colorectal cancer in these patients, and larger studies of transplant populations will be needed to determine these.

In line with current clinical practice, we chose a faecal immunochemical test (Insure, Enterix Australia) as a means to screen for colorectal neoplasia. The sensitivity and predictive value of this test were poor for advanced colorectal neoplasia, although specificity was better. Although several stools were sampled, testing was done on a one-off basis, and sensitivity could potentially be improved with serial testing.[@ref12] [@ref35] The Insure faecal immunochemical test has been found to have superior diagnostic accuracy for the detection of advanced colorectal neoplasia compared with sensitive guaiac faecal occult blood tests (such as Hemoccult II SENSA),[@ref18] and it can speed detection of interval cancers when used in a colonoscopy surveillance programme.[@ref35] In addition, it had the highest level of acceptability to patients in a randomised trial of participation in screening that included several different immunochemical tests,[@ref36] and it had a high screening uptake rate and acceptability to patients in the large Australian bowel cancer screening pilot.[@ref37]

The performance characteristics of immunochemical faecal haemoglobin tests to identify advanced colorectal neoplasia have been variable across a range of studies.[@ref38] [@ref39] [@ref40] [@ref41] However, a large study of a one-off faecal haemoglobin versus colonoscopy found a sensitivity and specificity for advanced neoplasia of 27.1% and 95.1%,[@ref40] comparable to our findings. Faecal haemoglobin thus seems to have similar diagnostic accuracy to detect advanced colorectal neoplasia in both the transplant and general populations. Factors such as sub-clinical colitis from cytomegalovirus infection or drug toxicity, or potentially microscopic haematuria, which might be present in some transplant recipients, most commonly in the early post-transplant period, do not seem to have resulted in any significant adverse effect on specificity in this predominantly long term post-transplant cohort.

In a case-control study of colonoscopy surveillance done as "usual care" in 315 kidney transplant recipients compared with 630 general population controls referred for screening colonoscopy (and therefore unlikely to be truly at "average risk" owing to referral bias), Park and colleagues reported prevalences of 7.0% for advanced adenomas and 1.9% for cancers.[@ref42] The odds ratios were 3.5 for advanced adenomas and 12.0 for cancers in screened transplant recipients. However, most of the transplant cohort were aged under 50, and such a population would be expected to have low rates of advanced colorectal neoplasia, compared with the older population included in our study.

Conclusions, policy implications, and questions for future research
-------------------------------------------------------------------

The findings of this study have important implications for the development of guidelines on screening for colorectal cancer in kidney transplant recipients. Although the sensitivity of the immunochemical faecal haemoglobin test is poor, its performance as a screening test for neoplasia in transplant recipients is comparable to that reported in studies of population screening, without any apparent loss of specificity. Colonoscopy seems to be safe to use as a surveillance tool in transplant recipients.

Given the difficulties and costs of doing studies of this type in transplant recipient populations, or indeed randomised interventional trials, definitive data to determine whether the benefits of screening outweigh the harms are unlikely to be available. Our study provides novel data that can be used in decision analyses and cost effectiveness studies to inform clinical practice guidelines, which to date have relied on extrapolations of general population data.[@ref26] [@ref28] In addition, long term follow-up of this cohort compared with an unscreened transplant population should provide comparative data on the outcomes of screening transplant recipients for colorectal cancer. From a payer's perspective, a simplistic analysis of our data would suggest that the estimated cost of detecting one advanced neoplasia through surveillance colonoscopy of transplant recipients, at an estimated cost of \$A1192 (£786; €990; \$1219) per procedure,[@ref43] would be \$A9536 (95% confidence interval \$A7152 to \$A14 304), but the cost effectiveness of such an approach is unknown. How transplant patients might regard surveillance colonoscopy is unclear, but the high participation rate here suggests that many are comfortable with this approach.

In conclusion, the main findings of this study are that a high prevalence of advanced colorectal neoplasia exists in kidney transplant recipients over the age of 50 and that, compared with when it is used in the general population, faecal haemoglobin screening of transplant recipients has similarly low sensitivity although acceptable specificity for neoplasia. Given the high prevalence of neoplasia, screening with faecal haemoglobin testing alone will miss significant lesions with the potential to develop into colorectal cancer. Taken together with previously reported increased risk of colorectal cancer and poor outcomes, these findings lead us to conclude that surveillance with colonoscopy may be the most appropriate approach to reduce the risk of colorectal cancer in kidney transplant recipients. Further studies are needed to assess the outcomes and costs of such an approach.

### What is already known on this topic

1.  Faecal haemoglobin screening in people over the age of 50 years reduces mortality from colorectal cancer in the general population

2.  Kidney transplant recipients, compared with the general population, have an increased risk of developing colorectal cancer and have inferior outcomes once cancer develops

3.  Data on the prevalence of colorectal neoplastic lesions and the diagnostic accuracy of faecal haemoglobin tests have been insufficient to enable guidelines to be developed on screening for colorectal cancer in kidney transplant recipients

### What this study adds

1.  Kidney transplant recipients aged over 50, at otherwise average risk, have a high prevalence of advanced colorectal neoplasia (13%), the precursor to most colorectal cancers

2.  Faecal haemoglobin screening for colorectal neoplasia in transplant recipients has a similar poor sensitivity (31.0%) to that reported in general population studies but reasonable specificity (90.5%)

3.  Colonoscopy surveillance rather than faecal haemoglobin screening may be a better option to reduce the risks of colorectal cancer in kidney transplant recipients
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